ライフサイエンスコーパス: pregnant women

1 n pregnant women compared to age-matched non-pregnant women.

2 cy outcomes were evaluated for a subgroup of pregnant women.

3 ing, supporting recommendations to vaccinate pregnant women.

4 tabolome of 784 weekly blood samples from 30 pregnant women.

5 sters with a high prevalence of unvaccinated pregnant women.

6 effect of pool walking on renal function in pregnant women.

7 eventing and managing bacterial infection in pregnant women.

8 nt, of which 124 (80%) specifically excluded pregnant women.

9 posures in Mexican populations, particularly pregnant women.

10 forts on preventing inadvertent treatment of pregnant women.

11 f disease are similar among pregnant and non-pregnant women.

12 sion and described 160 cases of plague among pregnant women.

13 n may increase the risk of RSV illness among pregnant women.

14 art of first-line antiretroviral therapy for pregnant women.

15 s, and an increased risk of preterm birth in pregnant women.

16 y of inflammatory infiltrate in lesions from pregnant women.

17 adverse events after ivermectin exposure in pregnant women.

18 place despite experience with these drugs in pregnant women.

19 uch correlation was seen in the normotensive pregnant women.

20 000 among pregnant and 7.3/100,000 among non-pregnant women.

21 in treatment for COVID-19, 27 (77%) excluded pregnant women.

22 onal studies that reported adverse events in pregnant women.

23 es, of which 538 (75%) specifically excluded pregnant women.

24 en, these relationships are underexplored in pregnant women.

25 of developing treatment recommendations for pregnant women.

26 and economic impact of seasonal influenza on pregnant women.

27 ected more than 10 million people, including pregnant women.

28 es, as changes of breast volume vary between pregnant women.

29 to further define pertussis epidemiology in pregnant women.

30 Among 958 980 pregnant women, 10% received opioids only, 6% psychotrop

31 In order to better characterize GDM in pregnant women, 100 blood plasma samples (50 GDM and 50

32 id content were determined in faeces from 35 pregnant women (14 with uncomplicated pregnancies and 21

33 Antiretroviral-naive pregnant women (20-<37 weeks gestation) living with HIV

34 her during epoch 1 than during epoch 2 in 70 pregnant women (23%) and in 23 controls (25%) (odds rati

35 mpaigns in the observational studies and 397 pregnant women (399 pregnancy outcomes) purposely receiv

36 pregancy outcomes were included, of whom 496 pregnant women (500 pregnancy outcomes) received ivermec

37 uman immunodeficiency virus (HIV)-uninfected pregnant women (68 IIV3 and 77 placebo recipients) and 1

38 Among pregnant women, 93% of those on mechanical ventilation w

39 Little is known about pertussis among pregnant women, a population at increased risk for sever

40 counts of >=10(5) CFU/ml in women, including pregnant women; a single voided urine specimen with one

41 Pregnant women accumulate substantial indirect costs tha

42 s (ARFI) and influenza-associated ARFI among pregnant women, administrative and electronic health rec

43 Contrary to current guidelines, most pregnant women admitted in the US with acute cholecystit

44 sectional analysis using 1992-2017 data from pregnant women admitted to treatment facilities for OUD

45 Pregnant women admitted with acute cholecystitis were id

46 e OT21 transmissometer (Magee Scientific) in pregnant women, adult women, and children < 1 year of ag

47 A total of 156 pregnant women (age 26.62 +/- 3.93 years) within the ges

48 All pregnant women aged >=15 years were followed-up during p

49 cohort included racially/ethnically diverse pregnant women (aged 20-45 years-33% primiparous, 37% bi

50 Consenting pregnant women, aged 12-49 years, were recruited in thei

51 We recruited non-pregnant women, aged 25 years or older, who were eligibl

52 We enrolled 351 pregnant women and 109 controls with epilepsy.

53 Among the 299 pregnant women and 93 controls who had a history of seiz

54 Trials excluded pregnant women and adults with severe kidney or liver di

55 d use of new drugs, prospective follow-up of pregnant women and birth surveillance studies such as Ts

56 ze seasonal influenza hospitalizations among pregnant women and can inform assessments of the public

57 Pregnant women and children are especially vulnerable to

58 description of productive efforts to include pregnant women and children in therapeutic and vaccine t

59 n deficiency continues to pose a problem for pregnant women and fetal development, an incomplete unde

60 tic drug was changed at least once in 74% of pregnant women and in 31% of controls (odds ratio, 6.36;

61 A random sample of 2,329 pregnant women and new mothers living in the study area

62 ng collected three times during pregnancy in pregnant women and older adult women.

63 f untreated asymptomatic bacteriuria include pregnant women and patients who undergo urologic procedu

64 example, the vulnerability of groups such as pregnant women and taught other lessons valuable for fut

65 feasibility of a large prospective study of pregnant women and their infants in order to understand

66 United States, and thus the unique needs of pregnant women and their infants should be considered in

67 gnancy are urgently needed to better protect pregnant women and their newborns.

68 protein-calorie food supplements offered to pregnant women and their offspring below the age of 6 ye

69 nutrition, supplemental nutrition offered to pregnant women and their offspring below the age of 6 ye

70 er potential to reduce the metabolic risk in pregnant women and their offspring.

71 cosanoids longitudinally across gestation in pregnant women and to determine whether levels differed

72 mmendations, coverage of syphilis testing in pregnant women and treatment of those found seropositive

73 Non-Hispanic Black pregnant women and women from Southern Central Valley ge

74 ly, in 31,841 children aged 1 to <18 y, 1262 pregnant women, and 7170 nonpregnant women aged 18-49 y.

75 representative sample of Colombian children, pregnant women, and adult nonpregnant women.

76 a inactivated vaccine (IIV3) immunization in pregnant women, and association with protection against

77 be based on demonstrating vaccine safety in pregnant women, and benchmarking immunogenicity against

78 cause of bacteremia and sepsis in newborns, pregnant women, and immunocompromised patients.

79 cific patient populations, such as children, pregnant women, and racial and ethnic minorities.

80 Pregnant women are advised against handling cat litter,

81 Pregnant women are an important at-risk population to co

82 Pregnant women are at increased risk of seasonal influen

83 jor public health concern given that ~40% of pregnant women are either overweight or obese.

84 Globally, 1.4 million pregnant women are estimated to be living with HIV/AIDS,

85 s for severe COVID-19 in adults, but data in pregnant women are limited.

86 nds in treatment data among justice-involved pregnant women are limited.

87 to increase influenza vaccine coverage among pregnant women are needed, particularly in vulnerable po

88 fspring, and given that approximately 25% of pregnant women are prescribed antibiotics, it is importa

89 A substantial proportion of pregnant women are prescribed opioids at doses that incr

90 ts with COVID-19 is increasing, many exclude pregnant women as participants or do not address pregnan

91 artum in a cohort of obese and normal-weight pregnant women, as well as in women with a history of RY

92 ussis (Tdap) vaccine was recommended for all pregnant women at >=20 weeks of gestation.

93 Pregnant women at 22 weeks' gestation or greater who wer

94 We are enrolling 800 pregnant women at each of the 4 international research c

95 acebo-controlled VD supplementation trial in pregnant women at high risk of offspring asthma (N = 806

96 effective strategy to identify HBV-infected pregnant women at risk of perinatal transmission in coun

97 s hinders the identification of HBV-infected pregnant women at risk of perinatal transmission.

98 Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 da

99 ion, whereas the ultimate beneficiaries were pregnant women attending ANC.

100 Pregnant women attending for antenatal care at less than

101 , delivered to a hypothetical cohort of 1000 pregnant women, averted 892 DALYs (95% credibility inter

102 ere lower than in the obese or normal-weight pregnant women (basal levels: 13.66 +/- 5.88 vs. 19.03 +

103 d a multicountry, randomized trial involving pregnant women between 26 weeks 0 days and 33 weeks 6 da

104 .IMPORTANCE Although Zika virus infection of pregnant women can result in congenital Zika syndrome, t

105 ptomatic children 5 years and younger and in pregnant women cannot be determined.

106 n high-income countries, those involving non-pregnant women, case reports, and studies published befo

107 oV-2 infection causes more severe disease in pregnant women compared to age-matched non-pregnant wome

108 e (HM) and 20 gestational-age-matched normal pregnant women (control).

109 screen-detected SARS-CoV-2 prevalence among pregnant women delivering in 2 New York City hospitals.

110 a multiomics analysis of 51 samples from 17 pregnant women, delivering at term.

111 RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success cri

112 ctyl phthalate [DOP] increased in California pregnant women during our study period.

113 AASDs) in children under three years old, or pregnant women during the third trimester, may adversely

114 ight and congenital anomaly) in HIV-infected pregnant women enrolled as controls in the Tshepiso stud

115 We analyzed data from 7553 HIV-negative pregnant women enrolled in a multivitamin trial at 12-27

116 udy, we collected participant-level data for pregnant women enrolled in the SUSTAIN and REFINE studie

117 ed in 2006 to evaluate perinatal outcomes in pregnant women exposed to omalizumab and their infants.

118 sed risk of major congenital anomalies among pregnant women exposed to omalizumab compared with a dis

119 sampled cohort of 613 pregnant and 1,969 non-pregnant women, focusing on 300 pregnant and 300 non-pre

120 ed in 18/121 (15%) children and 17/109 (16%) pregnant women following prenatal streptomycin exposure.

121 rotein requirements of well-nourished Indian pregnant women for a GWG of 12 kg in the second and thir

122 sed trial in Bangladesh in which we enrolled pregnant women from 2013 through 2015 covering 30,646 ne

123 Between 2007 and 2011, 948 pregnant women from Mexico City were recruited as part o

124 hnically, and socially diverse population of pregnant women from Northern California and the Central

125 Data for 92,743 pregnant women from the Japan Environment and Children's

126 In this study of >5,000 pregnant women from three cohorts, we aimed to identify

127 Pregnant women from Uganda and South Africa were randomi

128 The present study included 845 pregnant women from Wuhan, China (2013-2015), who provid

129 Pregnant women (>18 years of age) at 20-28 weeks' gestat

130 Pregnant women had the highest VDD prevalence at 6.7% +/

131 o middle-income country, but well-nourished, pregnant women have comparable requirements.

132 Cohort and case-controlled studies of pregnant women have demonstrated periodontal disease as

133 Obese pregnant women have dyslipidemia; however, whether obesi

134 al (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective conc

135 s inferred using tests administered to 1,746 pregnant women hospitalized for delivery between March 2

136 were analyzed from retrospective cohorts of pregnant women hospitalized with ARFI who had testing fo

137 y maternity service in London (UK), in which pregnant women identified at increased risk of PTB were

138 One to 2 pregnant women in 1000 will experience venous thromboemb

139 urine samples collected from 192 California pregnant women in 2007-2013 during their second and thir

140 olled trial in rural Bangladesh, we enrolled pregnant women in 4 arms: control, WSH, child nutrition

141 poses higher risks of hospitalization among pregnant women in all trimesters, compared with nonpregn

142 Including pregnant women in anti-helminthic treatment programs wou

143 V infection rates were highly variable, most pregnant women in Brazil during the ZIKV outbreak will h

144 Inclusion of pregnant women in clinical treatment trials is urgently

145 ever, the monitoring of the effect of ZVD on pregnant women in Colombia is ongoing.

146 Inclusion of pregnant women in COVID-19 clinical trials would allow e

147 attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order

148 randomized intervention trial enrolling 800 pregnant women in each of four countries (i.e., Peru, Gu

149 finitions to detect influenza in a cohort of pregnant women in India, Peru, and Thailand.

150 ticipant-level data from 1617 HIV-uninfected pregnant women in Kenya (one trial; n=806) and Uganda (t

151 evere pre-eclampsia in the PreCARE cohort of pregnant women in Paris (n = 9,579).

152 Pregnant women in settings with high HIV prevalence are

153 d, open-label trial, DolPHIN-2, we recruited pregnant women in South Africa and Uganda aged at least

154 nt linkage; the women were matched to 10,110 pregnant women in the general population (1:5) based on

155 ted from August 2013 to May 2016 among 3,967 pregnant women in the Tongji Maternal and Child Health C

156 out temporal trends of phthalate exposure in pregnant women in the United States.

157 the cost-effectiveness of HCV screening for pregnant women in the United States.

158 nding access to evidence-based treatment for pregnant women in the US.

159 irth weight (PLBW) delivery, we recruited 90 pregnant women in this prospective study.

160 We explored the inclusion of pregnant women in treatment trials of COVID-19 by review

161 been assessed in many risk groups, including pregnant women in whom influenza may manifest differentl

162 odenalis among children born to the enrolled pregnant women (index children) and their older siblings

163 From 2014 to 2018, we enrolled 179 pregnant women into 4 groups: "HLHS/TGA" fetuses with hy

164 ) gestational-age-specific BP charts for all pregnant women (irrespective of ethnicity) and for White

165 y, a hospital-based cohort study with 36,755 pregnant women is conducted.

166 Screening pregnant women is not recommended by the Society of Mate

167 or HIV infection in adolescents, adults, and pregnant women is substantial.

168 The primary concern for HIV-infected pregnant women is the vertical transmission that can occ

169 violence may indirectly affect health among pregnant women living in neighborhoods where it is endem

170 Data on the safety and efficacy of IPT in pregnant women living with HIV (PWLHIV) are mixed.

171 ty, low birth weight, congenital anomaly) in pregnant women living with HIV enrolled as controls in t

172 chedules of inactivated influenza vaccine in pregnant women living with HIV in South Africa.

173 More immunogenic vaccines are needed for pregnant women living with HIV to enhance transplacental

174 Between Feb 11, and June 6, 2013, 800 pregnant women living with HIV were enrolled and randoml

175 study, a prospective observational cohort of pregnant women living with HIV with and without tubercul

176 ransmission of HIV [eMTCT] and the health of pregnant women living with HIV) and repeat HIV testing (

177 erred or alternative integrase inhibitor for pregnant women living with HIV.

178 nogenicity than did a single-dose regimen in pregnant women living with HIV.

179 We enrolled pregnant women (<=20 weeks gestation) and followed them

180 e coronavirus 2 (SARS-CoV-2) infection among pregnant women making antenatal visits to 4 Boston, Mass

181 n a population of primarily Medicaid-insured pregnant women managed by a cardio-obstetrics team, mate

182 Fifteen pregnant women (mean gestational age, 37.8 weeks) walked

183 During the study period, 306 pregnant women (median age 29 years, 52.9% Hispanic or L

184 At baseline, 40% of pregnant women (median gestational age 28 weeks) require

185 dentition, and improving vitamin D status in pregnant women might affect ECC rates in their infants.

186 ring these campaigns with recommended doses, pregnant women might be inadvertently exposed.

187 In a subgroup of 1850 pregnant women, more than 90% of women who were reported

188 Pregnant women (n = 1,185) completed a questionnaire and

189 e-matched controls (n = 17), and healthy non-pregnant women (n = 10).

190 ur data come from a case-control study of 90 pregnant women nested within the LIFECODES prospective b

191 pediatric populations (age < 16 years old), pregnant women, noncritically ill patients, very specifi

192 h those from a disease-matched population of pregnant women not treated with omalizumab.

193 e; and a longitudinally sampled cohort of 90 pregnant women of African or non-African ancestry.

194 women, focusing on 300 pregnant and 300 non-pregnant women of African, Hispanic or European ancestry

195 ertussis epidemiology among pregnant and non-pregnant women of childbearing age.

196 e increased during pregnancy compared to non-pregnant women of childbearing age.

197 des and bisphenol A (mixture N1) detected in pregnant women of the SELMA cohort and associated with l

198 n nutritional recommendations, counseling of pregnant women on diet and physical activity recommendat

199 ementation in mildly-to-moderately deficient pregnant women on maternal and infant thyroid function a

200 A sample of 105 pregnant women participated in human fetal resting-state

201 Pool walking may improve renal function in pregnant women partly through the suppressed renin-angio

202 In a cohort of pregnant women patterns of allergic sensitization in adu

203 e SARS-CoV-2 test results among asymptomatic pregnant women presenting for labor and delivery at Yale

204 Prophylactic vaccination of pregnant women prior to delivery could provide comprehen

205 llular vesicles (sEVs) isolated from healthy pregnant women promote islet glucose-stimulated insulin

206 Consistent with the findings from pregnant women, PTB is successfully reproduced in mice w

207 rted prevalence of bacterial vaginosis among pregnant women ranges from 5.8% to 19.3% and is higher i

208 MoBa includes about 95,000 pregnant women recruited throughout Norway from 1999 to

209 Improving access to medications for OUD for pregnant women referred by criminal justice agencies cou

210 he study period, 26.3% (95% CI 25.7-27.0) of pregnant women referred by criminal justice agencies rec

211 Among pregnant women referred by criminal justice agencies, re

212 examine trends in medications for OUD among pregnant women referred to treatment by criminal justice

213 t the epidemiology of severe influenza among pregnant women remain largely limited to pandemics.

214 udies for COVID-19, the proportion excluding pregnant women remains consistent.

215 Uptake of influenza vaccine among pregnant women remains low.

216 urrent WHO policy for iron administration to pregnant women should remain unchanged while more effect

217 A total of 397 pregnant women suffered from severe maternal outcomes am

218 iepileptic drugs occurred more frequently in pregnant women than in nonpregnant women during similar

219 nt preventive treatment (IPTp) of malaria in pregnant women that compared dihydroartemisinin-piperaqu

220 natal glucocorticoid therapy administered to pregnant women threatened with preterm birth is also dis

221 veloped Markov models of HIV and syphilis in pregnant women to estimate costs and infant health outco

222 activity programs with optimal intensity for pregnant women to prevent and treat their psychological

223 ced on reducing transmission to seronegative pregnant women to prevent vertical transmission and its

224 the Environment (HOME) Study randomized 355 pregnant women to receive an intervention to reduce eith

225 In 2017 and 2018, we contacted 11,277 pregnant women twice weekly during the influenza season

226 dertook a prospective study enrolling normal pregnant women undergoing elective caesarean section.

227 er in normo-weight and in normolipemic obese pregnant women using stable isotopes.

228 Among pregnant women, VDD was positively related to education.

229 Universal HCV rescreening among pregnant women was cost-effective (ICER $6,000/QALY) and

230 fetal priming with tetanus vaccine given to pregnant women, was comparable in HIV-exposed and non-HI

231 In conclusion, unvaccinated pregnant women were clustered geographically and by key

232 We investigated whether unvaccinated pregnant women were clustered geographically and determi

233 Pregnant women were eligible if they were aged 18-38 yea

234 Results A total of 2952 pregnant women were evaluated.

235 Placentas from 134 pregnant women were examined after delivery for patholog

236 infected (72 IIV3 and 68 placebo-recipients) pregnant women were independently randomised in placebo-

237 A total of 4631 pregnant women were recruited (IG, n = 2565; and CG, n =

238 Between March 2007 and December 2010, pregnant women were recruited to BiB during routine ante

239 Pregnant women were recruited, and maternal scores on th

240 Pregnant women were screened for Chagas disease by rapid

241 cal characteristics of COVID-19 pneumonia in pregnant women were similar to those reported for non-pr

242 ecific study seasons), only 1030 (6%) of the pregnant women were tested for influenza viruses by rRT-

243 More than half (53%) of the 77,607 included pregnant women were unvaccinated.

244 Overall, 44 clusters (69 330 pregnant women) were randomly assigned to intervention (

245 with child cognitive outcomes, are needed in pregnant women who are moderately deficient (median UIC

246 All pregnant women who attended their first antenatal visit

247 An uncommon but important complication in pregnant women who become acutely infected with Brucella

248 od for HIV acquisition in African women, and pregnant women who become acutely infected with HIV acco

249 study in a referral center by collecting all pregnant women who diagnosed as pre-eclampsia and delive

250 ma collected longitudinally from children of pregnant women who had been followed closely through pre

251 Pregnant women who were members of Kaiser Permanente Nor

252 data exist about the role of betatrophin in pregnant women with a history of Roux-En-Y gastric bypas

253 There were 6390 pregnant women with acute cholecystitis: 38.2% underwent

254 The rates of in-hospital mortality among pregnant women with acute stroke decreased (5.5% in 2007

255 1196 pregnant women with AMSB underwent a 21-24 week "placent

256 ic, and fetal events during delivery between pregnant women with and without CHDs in the United State

257 pective observational cohort of HIV-infected pregnant women with and without TB disease in Soweto, So

258 an Heart Association recommends providers of pregnant women with CHD assess cardiac health and discus

259 prescriptions, and adverse conditions among pregnant women with CHD compared with those without CHD.

260 Contemporary outcomes of pregnant women with cirrhosis and their infants, as well

261 nary teams are needed to coordinate care for pregnant women with cirrhosis during pregnancy and postp

262 Fewer than 2% of pregnant women with cirrhosis had liver-related complica

263 We identified pregnant women with compensated cirrhosis (n = 2022) usi

264 Pregnant women with congenital heart defects (CHDs) may

265 Limited data are available for pregnant women with COVID-19 pneumonia.

266 ing the potential for severe morbidity among pregnant women with COVID-19.FUNDINGBeatrice Kleinberg N

267 Pregnant women with heart disease are at risk for seriou

268 ncidence of serious cardiac events (SCEs) in pregnant women with heart disease, whether they were pre

269 Our findings suggest that among HIV-negative pregnant women with high uptake of long-lasting insectic

270 , randomised, controlled trial, we recruited pregnant women with HIV from seven antenatal clinics in

271 (68 IIV3 and 77 placebo recipients) and 140 pregnant women with HIV infection (72 IIV3 and 68 placeb

272 Vaginal microbial communities of pregnant women with HIV were significantly more diverse

273 isoniazid therapy to prevent tuberculosis in pregnant women with human immunodeficiency virus (HIV) i

274 Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective,

275 Pregnant women with inflammatory bowel disease (IBD) may

276 Results from 15 pregnant women with ITP (pregnancies, n = 17; neonates,

277 scans were retrospectively reviewed for nine pregnant women with laboratory-confirmed COVID-19 pneumo

278 In pregnant women with laboratory-confirmed ZVD, brain or e

279 We randomised inner-city pregnant women with metabolic risk factors (obesity, chr

280 from the Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy

281 ase-control study was conducted including 33 pregnant women with mid-trimester maternal plasma (gesta

282 c index (GI) diet plus physical activity) in pregnant women with obesity (294 contol, 263 interventio

283 ietary and physical activity intervention in pregnant women with obesity modified the methylation sig

284 Criminal justice involvement is common among pregnant women with opioid use disorder (OUD).

285 Pregnant women with OUD referred by criminal justice age

286 n March 21 to June 16, 2020 for hospitalized pregnant women with PCR-confirmed SARS-CoV-2 infection a

287 ted a retrospective study of 690 consecutive pregnant women with positive T. gondii IgG antibody test

288 t outcome were analyzed in a database of 304 pregnant women with primary infection.

289 In the cohort of pregnant women with RYGB and exaggerated risk of postpra

290 r disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use

291 We describe outcomes in the first 86 pregnant women with severe COVID-19 who were treated wit

292 lts emphasize the need to treat or prophylax pregnant women with suspected plague with highly effecti

293 d cardiovascular readmissions in a cohort of pregnant women with underlying cardiovascular disease (C

294 ational surveillance data regarding cases of pregnant women with ZVD that were reported during the pe

295 A total of 11,944 pregnant women with ZVD were reported in Colombia, with

296 Of 18,117 pregnant women with ZVD, the presence of Zika virus was

297 A total of 4,326 pregnant women, with documented evidence of recruitment

298 emented nationwide malaria screening for all pregnant women within the antenatal care system.

299 han historical data from the same setting in pregnant women without HIV.

300 In comparison to normal-weight and obese pregnant women, women with a history of RYGB operation a